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The simian virus 40 large tumor antigen (T-ag) is found in both the nuclei (nT-ag) and plasma membranes
(mT-ag) of simian virus 40-infected or -transformed cells. It is not known how newly synthesized T-ag
molecules are recognized, sorted, and transported to their ultimate subcellular destinations. One possibility is
that these events depend upon structural differences between nT-ag and mT-ag. To test this possibility, we
compared the structures of nT-ag and mT-ag from simian virus 40-infected cells. No differences between the
two forms of T-ag were detected by migration in polyacrylamide gels, by Staphylococcus aureus V8 partial
proteolytic mapping of methionine- or proline-containing peptides, or by two-dimensional tryptic peptide
mapping of methionine-containing peptides. The carboxy-terminal, methionine-containing tryptic peptide was
identified in the two-dimensional maps and was shown to be identical in nT-ag and mT-ag. Thus, a structural
basis for the recognition and differential localization of T-ags could not be demonstrated. The carboxy terminus
of the T-ag encoded by mutant dL42413 is derived from the alternate open reading frame of the simian virus
40 early region, in analogy with the theoretical early gene product, T*-ag. We used this mutant to identify
peptides unique to T*-ag. None of these peptides were detected in maps of mT-ag; only wild-type T-ag-specific
peptides were found. These findings suggest that T*-ag does not represent the membrane-associated form of
T-ag, but that mT-ag is encoded within the same reading frame used for nT-ag.
The large tumor antigen (T-ag) is the transforming protein
of simian virus 40 (SV40); this antigen is the only viral gene
product which is absolutely required for the initiation and
maintenance of cell transformation (33, 60). T-ag is a
multifunctional protein and exhibits many different biochemical and biological activities (43). The T-ag polypeptide may
undergo a variety of chemical modifications (13, 14, 19, 36,
57) and can assume discrete supramolecular forms (10, 34,
41). Thus, T-ag has the potential for considerable structural
diversity, which might explain its ability to perform multiple
functions. Another factor that might contribute to the
multifunctional capacity of T-ag is its differential subcellular
localization. The majority (>95%) of T-ag is localized within
the nuclei of host cells (nT-ag) (40, 42), but a small fraction
is associated with the plasma membranes (mT-ag) (3, 8, 46,
53, 59). Recent studies have shown that SV40 mutants
expressing T-ags which are not transported to the nucleus
cannot transform primary rodent cells (11, 27). One interpretation of that finding is that nT-ag and mT-ag may play
separate roles in cellular transformation and cooperate to
induce the expression of the fully transformed phenotype.
The mechanism by which newly synthesized T-ag molecules are recognized and transported to different subcellular
locations is poorly understood. It is known that T-ag contains a strong nuclear transport signal, which is found
between amino acids 127 and 133 in the amino-terminal one
third of the protein (16, 25). However, the point at which
nT-ag and mT-ag diverge and are targeted to different
subcellular compartments and the pathways involved in their
transport are unknown. It is possible that some structural
*

difference exists between the two forms of T-ag which
mediates their specific recognition and subsequent localization.
A prime candidate for a structurally unique form of T-ag
was suggested by Mark and Berg (32). These authors described a third species of SV40 early mRNA which was
similar to the mRNA encoding T-ag, but had undergone an
additional splicing event around 0.20 map unit. This mRNA
could theoretically encode a protein, designated T*-ag,
which would differ from T-ag as the result of a change in
reading frame at the point of the splice. Significantly, the
carboxy terminus of the putative T*-ag molecule would be
more hydrophobic than the carboxy terminus of T-ag. It was
proposed that T*-ag might be the membrane-associated form
of T-ag, since its hydrophobic carboxy terminus could
provide a membrane-anchoring function, in accord with the
structural requirements of integral plasma membrane proteins. T*-ag has not been detected in wild-type (WT) SV40infected or -transformed cells (7). However, the carboxy
terminus of the T-ag encoded by a deletion mutant of SV40,
dlA2413, is derived from the alternate open reading frame
and closely resembles the theoretical T*-ag of WT SV40

(61).

We compared the structures of nT-ag and mT-ag that were
isolated from subcellular fractions of WT SV40-infected cells
in an attempt to explain the intracellular sorting of T-ag. We
did not detect any differences between the two forms,
suggesting that their structures are similar or identical.
Hence, we could not identify a structural basis for recognition and differential transport of these molecules. We also
used dlA2413 to characterize the structure of T*-ag. As
expected, T*-ag was different from WT T-ag, and unique
peptides were identified. None of the T*-ag unique peptides
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were detected in maps of WT mT-ag; only WT T-ag-specific
peptides were found. We concluded that T*-ag does not
represent the membrane-associated form of T-ag, but that
mT-ag is encoded within the same reading frame used for
nT-ag.

MATERIALS AND METHODS
Cells and viruses. Clone TC-7 of CV-1 cells (44) was
propagated in enriched Eagle minimal essential medium
(GIBCO Laboratories, Grand Island, N.Y.) (37). COS-1 cells
(12) were propagated in Dulbecco minimal essential medium
(GIBCO) supplemented with 10% fetal bovine serum
(GIBCO), 0.3% sodium bicarbonate, and 25 p.g of gentamicin
sulfate (Schering Corp., Bloomfield, N.J.) per ml.
WT SV40 (Baylor reference strain) (56) and SV40 d11263
(6) were passaged at low multiplicities of infection and were
titrated in TC-7 cells (38). Virus stocks were prepared from
SV40 dlA2413 DNA (61) in COS-1 cells, as previously
described (4). Briefly, plasmid DNA was extracted fromEscherichia coli HB101, separated from chromosomal DNA,
and partially purified by hydroxylapatite column chromatography (25). The eluted plasmid was dialyzed against TE
buffer (10 mM Tris hydrochloride, 1 mM EDTA pH 8.0),
ethanol precipitated, and dissolved. Viral sequences were
excised from the plasmid by treatment with EcoRI (Bethesda
Research Laboratories, Inc., Gaithersburg, Md.), circularized at a low concentration (3 ,ug/ml) with T4 DNA ligase
(Bethesda Research Laboratories), and ethanol precipitated
from the reaction mixture. COS-1 cells which were about
50% confluent in 60-mm petri dishes were transfected with
the DNA preparation in the presence of 200 ,ug of DEAEdextran (molecular weight, 2 x 106; Sigma Chemical Co., St.
Louis, Mo.) (52) per ml. At 3 days after transfection. the
cells were freeze-thawed three times, the lysate was clarified, and the supematant was harvested. The supernatant
was then serially passaged in COS-1 cells until cytopathic
effects were observed within 3 days after infection.
Antisera. Normal hamster serum (NHS) and polyclonal
antiserum against SV40 T-ag (hamster ascites fluid [HAF])
have been described previously (22).
Infections and metabolic labeling conditions. Confluent
TC-7 monolayers were inoculated with 50 PFU of WT SV40
per cell or 50 PFU of SV40 dl1263 per cell or with 2 ml of
undiluted SV40 dlA2413 per 107 cells. The infected cells
were labeled from 21 to 24 h postinfection with 200 ,uCi of
[35S]methionine (1,000 to 1,500 Ci/mmol; Amersham Corp.,
Arlington Heights, Ill.) per ml or 100 jxCi of [14C]proline (250
mCi/mmol; ICN Pharmaceuticals, Inc., Irvine, Calif.) per ml
as previously described (15).
Subcellular fractionation. Nuclear and plasma membraneenriched fractions were prepared by the aqueous two-phase
polymer method (1, 24, 53). Cells were removed from culture
vessels with EDTA, washed, and swollen in 10-3 M ZnCl2.
After chilling, the cells were homogenized on ice in a
Dounce homogenizer with a tight-fitting pestle. About 100 to
200 strokes were usually required to break >90% of the
cells, as monitored by phase-contrast microscopy. The homogenate was centrifuged for 15 min at 1,500 x g to obtain
cytoplasmic (supernatant) and particulate (pellet) fractions.
The pellet was suspended in the top polymer phase and then
mixed with the bottom polymer phase, and the phases were
separated by centrifugation for 10 min at 8,500 rpm in a
model HB-4 swinging-bucket rotor (Sorvall Instruments, E.
I. du Pont de Nemours & Co., Inc., Newtown, Conn.). The
nuclear pellet was suspended and washed twice with Tris-
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buffered Nonidet P-40 (10 mM Tris hydrochloride, 140 mM
NaCl, 1.5 mM MgCl2, 0.5% Nonidet P-40, pH 6.5) to remove
cytoplasmic tabs. The membrane band at the polymer
interphase was banded three times by removing the supernatant, mixing, and repeating the centrifugal separation of
the two phases. The final membrane band was removed with
a pipette, diluted with Tris-buffered saline (2), and pelleted.
The nuclear and membrane fractions were solubilized by
sonication in extraction buffer (50 mM Tris hydrochloride,
100 mM NaCl, 1% Nonidet P-40, pH 8.0) (58) supplemented
with 0.1% sodium dodecyl sulfate (SDS), 1.0% sodium
deoxycholate, and 200 ,uM leupeptin (15). The extracts were
then clarified by centrifugation for 10 min in a model 235A
microfuge (Fisher Scientific Co., Pittsburgh, Pa.) prior to
immunoprecipition.
Extraction, immunoprecipitation, and gel electrophoresis.
T-ag was extracted from unfractionated, infected cells with
extraction buffer containing 200 ,uM leupeptin, and the
resulting extracts were clarified. Whole-cell extracts or
extracts of subcellular fractions prepared as described above
were then treated with HAF and fixed Staphylococcus
aureus strain Cowan I (18) to immunoprecipitate T-ag, and
the resulting immunoprecipitates were washed and disrupted
as previously described (14). The disrupted immunoprecipitates were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) (53), using 8% acrylamide gels, and the T-ag
bands were located by autoradiography of unfixed gels.
Reconstruction experiments. The efficacy of the aqueous
two-phase polymer method for the separation of the nT-ag
and mT-ag from infected cells was confirmed in a reconstruction experiment modeled after our previous studies (24, 46,
53, 55). Two roller bottles containing about 108 confluent
TC-7 cells each were infected with SV40. One of these
preparations was labeled with [35S]methionine, whereas the
other was not. The labeled cells were fractionated at 24 h
postinfection by the two-phase method to obtain cytoplasmic, nuclear, and membrane fractions, and 10% of the
cytoplasmic fraction, 10% of the nuclear fraction, and 100%
of the membrane fraction were extracted, immunoprecipitated for T-ag, and analyzed by SDS-PAGE. The remainder
of the labeled nuclei (90% of the starting material) was added
to the suspension of unlabeled, infected cells from the
second roller bottle. The resulting suspension was then
immediately homogenized and fractionated. Cytoplasmic,
nuclear, and membrane fractions were again obtained, and
these fractions were analyzed as described above for the first
set of fractions. The amount of radioactive T-ag obtained
from each fraction was quantitated by excising and solubilizing the T-ag bands (31) and then assaying the samples by
liquid scintillation spectroscopy.
Preparation and analysis of peptides. Partial proteolytic
cleavage maps of [35S]methionine- or [14C]proline-labeled
T-ag were prepared by the method of Cleveland et al. (5).
T-ag bands were excised from 8% acrylamide gels, cut in
half, and equilibrated for 1 h at room temperature in gel
sample buffer (0.05 M Tris hydrochloride, 4% SDS, 10%
glycerol, 1 mg of bromphenol blue per ml, pH 6.5). Each
one-half of a band was then loaded into a well on a 15%
acrylamide gel and overlaid with sample buffer containing
different amounts of S. aureus strain V8 protease (Sigma).
The concentrations of strain V8 protease which were most
appropriate for mapping T-ag were empirically determined
to be 0.5, 5.0, and 50 ,ug/ml. The samples were electrophoresed about halfway into the stacking gel, and the current
was turned off for 30 min to allow digestion to occur.
Electrophoresis was then completed, and the gels were
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impregnated with Autofluor (Natio nal Diagnostics,
Somerville, N.J.), dried, and exposed to IKodak XAR film at
-700C.
Tryptic peptide digests of [35SJmethi onine-labeled T-ag
were prepared and resolved in two dimen sions as previously
described (15, 51).
RESULTS
Isolation of nT-ag and mT-ag. The aiqueous two-phase
polymer method (1) has been used in our laboratory to
isolate nuclear and plasma membrane-eniriched fractions of
cultured cells (24, 53, 54). The atbsence of crosscontamination in the fractions was verified by using
[3H]thymidine and Na+-K+-ATPase as nnarkers for the nuclear and plasma membrane subcellular compartments, respectively (53). Importantly, it also was esstablished thatT-ag
does not nonspecifically copurify with th te nuclear or membrane fraction. This was accomplished b)y a reconstruction
experiment in which an extract containinjg a large amount of
radioactively labeled T-ag was added t() intact, unlabeled
cells, and the cells were processed by the usual fractionation
procedure. An analysis of the resulting fractions revealed
that the radioactive T-ag was found ornly in the soluble,
cytoplasmic fraction; no T-ag copurified with the nuclei or
membranes.
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FIG. 1. Reconstruction experiment to vallidate the subcellular
fractionation procedure for SV40-infected cells. (A) Cytoplasmic
(C), nuclear (N), and membrane (M) fractions were prepared from
about 108 SV40-infected, [35S]methionine-labeled cells by the aqueous two-phase polymer method. The fractions were extracted and
clarified, and then 10% of the cytoplasmic and nuclear fractions and
100%o of the membrane fraction were immunoprecipitated with HAF
and analyzed on an 8% acrylamide gel. (B) The remaining 90% of the
labeled nuclei from the first fractionation was added to a suspension
containing about 108 unlabeled, SV40-infected cells. The suspension
was immediately fractionated by the two-phase method, and cytoplasmic (C), nuclear (N), and membrane (M) fractions were analyzed as described above for the first set of fractions. Note that
labeled nT-ag did not copurify with the membrane fraction. The
positions of molecular weight markers are indicated on the left.

TABLE 1. Quantitative distribution of [V15S]methionine-labeled
T-ag in a reconstruction experiment
Fraction"

Radioactivity
X 101)

% Of total"

Cytoplasmic
Nuclear
Membrane

47.5
558
0.69

4.4
51.2
0.06

(cpm,

1' T-ag bands from the subcellular fractions prepared from a mixture of

[35S]methionine-labeled, infected cell nuclei and unlabeled, infected cells were
recovered from the gel shown in Fig. 1B. The bands were solubilized, and
radioactivity was quantitated by liquid scintillation spectroscopy.
"
Percentages were based on the total input of labeled nuclei, which
contained about 1.09 x 106 cpm.

In the present study, we evaluated the efficacy of the
two-phase method for infected cells by using a modification
of the reconstruction experiment. Our objective was to
isolate nT-ag and mT-ag for structural analyses. Since mT-ag
represents only a small proportion of the total cellular T-ag,
it was critical to determine whether nT-ag, which might be
released from nuclei during the fractionation procedure,
copurified with the membranes. As described in Materials
and Methods, nuclei were prepared from [35S]methioninelabeled, infected cells and mixed with an unlabeled, infected
cell suspension, and the mixture was processed by using the
two-phase procedure. The vast majority of the added radioactive nT-ag was found in the nuclear fraction; virtually none
was detected in the cytoplasmic or membrane fractions (Fig.
1). Quantitatively, 51.2% of the input radioactivity was
recovered in the nuclear fraction; only 4.4 and 0.06% were
recovered in the cytoplasmic and membrane fractions, respectively (Table 1). Our findings clearly indicated that
contamination of the membrane fraction with nT-ag was
minimal. In fact, this experiment probably overestimated the
extent of contamination, because the nuclei from the labeled
cells were subjected to two consecutive rounds of homogenization, which would have increased the probability of
damage and the release of more T-ag into the homogenate.
The total recovery of radioactive T-ag in the nuclear fraction
was rather low (51.2%), probably because we harvested only
the first nuclear pellet from the two-phase separations (more
nuclei were present in each of the subsequent pellets). In
addition, some T-ag may have been lost during washing of
the nuclei with Tris-buffered Nonidet P-40.
We did not consider the reciprocal possibility of contamination of the nuclear fraction with mT-ag to be a problem.
First, it is likely that membrane fragments adhering to
purified nuclei would be removed when the nuclei were
washed with Tris-buffered Nonidet P-40. Second, even if
contamination occurred, the contribution of T-ag from the
membrane fraction would be insignificant within the vastly
larger nT-ag pool.
Immunoprecipitation and SDS-PAGE analysis of various
forms of T-ag. SV40-infected cells were labeled with
[35S]methionine, and then nuclear and membrane fractions
were prepared by the two-phase procedure. The fractions
were extracted and immunoprecipitated with anti-T-ag serum (HAF), and the immunoprecipitates were analyzed by
SDS-PAGE (Fig. 2A). The major band of radioactivity in
each fraction was T-ag, which migrated with an apparent
molecular weight of about 88,000 (88K). This band was not
detected when NHS was used for immunoprecipitation or
when fractions were prepared from mock-infected cells (data
not shown). As expected, a much smaller amount of T-ag
was recovered from membranes than from nuclei. The two
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FIG. 2. Electrophoretic migration of various forms of T-ag. (A) Nuclear (NUC) and membrane (MEM) fractions were prepared from
[35S]methionine-labeled, WT SV40-infected cells, and then T-ag was extracted and immunoprecipitated with HAF. Disrupted immunoprecipitates were analyzed on 8% acrylamide gels. (B) Whole-cell extracts were prepared from WT SV40-, SV40 dlA2413-, or mock-infected,
[35S]methionine-labeled cells and then treated with NHS (N) or HAF (T), and disrupted immunoprecipitates were analyzed on 8%
polyacrylamide gels. The positions of molecular weight markers are indicated on the left.
as indicated by their identical migration in
polyacrylamide gels.
In a separate experiment, whole-cell extracts were prepared from WT SV40-, mutant dlA2413-, and mock-infected
cells. Each extract was immunoprecipitated with NHS or

brane fractions,

mT-ag bands shown in Fig. 2A represent the total amount of
mT-ag from about 2 108 infected cells, whereas the nT-ag
bands represent only 30% of the total nT-ag from the same
cells. There appeared to be no major structural differences
between the T-ag species isolated from nuclear and memx

B

A

V8
T-ag

0a5

0

n m

n

5.O
m

n

50

5&O

0.5

0

50

WT T* WT T* WT T* WT T*

m

I

I-

II'li
a

*

_

09

a

b

c

d

e

f

g

h

a

b

c

d

e

f

g

h

FIG. 3. Analysis of methionine-containing partial peptides of various forms of T-ag. (A) T-ag was isolated from nuclear (n) or membrane
(m) fractions of SV40-infected, [35S]methionine-labeled cells by immunoprecipitation and gel electrophoresis. Maps were prepared by treating
preparations with 0, 0.5, 5.0, or 50 p.g of V8 protease per ml as described in Materials and Methods. (B) V8 protease maps of T-ags isolated
from whole-cell extracts of [I3S]methionine-labeled cells infected with WT SV40 (WT) or SV40 dlA2413 (T*). The arrowheads indicate the
positions of peptides unique to WT T-ag or T*-ag.
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FIG. 4. Analysis of proline-containing partial peptides of nT-ag and mT-ag. T-ags were isolated from nuclear (nT-ag) or membrane (mT-ag)
fractions of WT SV40-infected cells labeled with [14C]proline. V8 protease maps were prepared as described in Materials and Methods. (C)
Overexposure of panel B.

HAF, and the immunoprecipitates were analyzed by SDSPAGE (Fig. 2B). Again, WT T-ag migrated at about 88K. In
contrast, the major HAF-reactive protein from dIA2413infected cells migrated at about 80K. Based upon its reactivity with HAF but not with NHS and its absence in
mock-infected cell lysates, we identified the 80K protein as
T*-ag. This result is in agreement with previous reports
which indicated that T*-ag migrates faster in polyacrylamide
gels than WT T-ag, even though its predicted molecular
weight is slightly higher (29, 61).
The difference in apparent molecular weight allowed us to
examine membrane preparations for evidence of T*-ag.
There was no detectable band corresponding to the 80K
protein in these preparations (Fig. 2A), suggesting that T*-ag
does not account for mT-ag. However, since a putative
membrane form of WT T*-ag might not be identical to
dIA2413 T*-ag and might behave differently from T*-ag
isolated from whole-cell extracts, additional analyses were
necessary.

Partial peptide mapping of various forms of T-ag. Partial
peptide maps were prepared by using S. aureus V8 protease
digestion, as described in Materials and Methods. The
patterns obtained from [35S]methionine-labeled nT-ag and
mT-ag were identical (Fig. 3A), suggesting that the structures of these molecules are quite similar. The patterns were
highly reproducible at each of the V8 protease concentrations used. In addition, a large number of peptides were
generated, suggesting that the analysis provided good sensitivity.
An analogous comparison of the T-ags isolated from
whole-cell extracts of WT SV40- or dlA2413-infected cells
revealed clear differences (Fig. 3B). WT T-ag contained one
peptide that was missing in dlA2413 T*-ag (Fig. 3B, lanes c,
e, and g, arrowheads), and dlA2413 T*-ag contained one
peptide that was missing in WT T-ag (Fig. 3B, lanes d, f, and

h, arrowheads). This difference provided another means of
detecting the presence of T*-ag in mT-ag preparations. The
WT T-ag-specific peptide was clearly present in the mT-ag
map (Fig. 3A, lane h, arrowhead), whereas the T*-agspecific peptide was not. The upper peptide of a doublet
specific to WT T-ag is also indicated in Fig. 3A (lane f,
arrowhead); the T*-ag-specific peptide is located above this
doublet (Fig. 3B) and is absent in the mT-ag map. Thus,
mT-ag contained only WT T-ag peptides; no evidence of
T*-ag was detected.
To confirm and extend the results obtained with methionine labeling, V8 peptide maps were prepared by using
['4C]proline-labeled nT-ag and mT-ag. Again, the two patterns were indentical (Fig. 4). The predicted amino acid
sequences of WT T-ag and T*-ag dictated that their prolinecontaining V8 peptides would be different. We did not
prepare a map of proline-labeled dIA2413 T*-ag, because
[14C]proline is costly and large amounts of sample are
required due to the low specific activity of the isotope.
However, since the WT nT-ag and mT-ag maps were identical, no evidence of T*-ag was detected among the prolinecontaining V8 peptides of mT-ag.
Two-dimensional tryptic peptide mapping of various forms
of T-ag. Different forms of T-ag were analyzed at a higher
level of sensitivity be using two-dimensional tryptic peptide
mapping. [35S]methionine-labeled T-ags were partially purified by immunoprecipitation and SDS-PAGE, recovered
from the gels, oxidized, and exhaustively digested with
trypsin. The peptides were then resolved in two dimensions
by high-voltage electrophoresis and ascending chromatography.
Maps of nT-ag and mT-ag are shown in Fig. 5A and B,
respectively, and both of these maps contain 17 clearly
resolved, highly reproducible peptides, in good agreement
with our previously published maps of T-ag (15). Other
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peptides were found, but these peptides were much less
reproducible and probably represented incomplete digestion
products. A consensus pattern is shown in Fig. 5C; the solid
spots represent the 17 highly reproducible peptides, and the
cross-hatched spots represent the less reproducible peptides. Identical results were obtained with several different
nT-ag and mT-ag preparations (data not shown); no structural differences were detected. The highly reproducible
peptides were always present on maps of either protein,
whereas the less reproducible peptides were found on occasion but were not consistent among different preparations.
Maps of methionine-labeled WT T-ag and dlA2413 T*-ag
from whole-cell extracts of infected cells are shown in Fig. 6.
The patterns obtained for WT T-ag by using either whole-cell
extracts or subcellular fractions were identical (Fig. 5A and
B and Fig. 6A). However, the dlA2413 T*-ag map was
clearly different (Fig. 6B); it contained at least three additional peptides that were not found in WT T-ag and lacked
one of the highly reproducible WT T-ag peptides (Fig. 6A
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FIG. 5. Two-dimensional analysis of the methionine-containing
tryptic peptides of nT-ag and mT-ag. T-ags were isolated from
nuclear or membrane fractions of WT SV40-infected,
[5S]methionine-labeled cells by immunoprecipitation and gel electrophoresis. The T-ag bands were excised from unfixed gels, eluted,
and concentrated. The protein was then oxidized and exhaustively
trypsinized, and peptides were resolved in two dimensions as
described in Materials and Methods. (A) nT-ag. (B) mT-ag. (C)
Consensus pattern of methionine-containing tryptic peptides of WT
T-ag. Highly reproducible peptides are indicated by solid spots and
numbered 1 through 17. Less reproducible peptides are indicated by
cross-hatched spots.
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FIG. 6. Two-dimensional analysis of the methionine-containing
tryptic peptides of WT T-ag and T*-ag. WT T-ag or T*-ag was
isolated from whole-cell extracts of [35S]methionine-labeled cells
infected with WT SV40 or SV40 dIA2413, and tryptic peptides were
prepared and analyzed as described in the legend of Fig. 5. (A) WT
T-ag. (B) T*-ag. The arrowheads indicate differences in the two
peptide maps.
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and B, arrowheads). The WT mT-ag map (Fig. SB) clearly
and reproducibly contained the WT T-ag-specific peptide
that was missing on the dIA2413 T*-ag map and lacked the
T*-ag-specific peptides. Thus, the two-dimensional tryptic
peptide maps confirmed the results of the previous analyses,
demonstrating that mT-ag is structurally very similar or
identical to nT-ag and contradicting the hypothesis that
T*-ag might account for mT-ag.
Identification of the carboxy-terminal, methioninecontaining tryptic peptide of T-ag. Tryptic peptides from the
carboxy-terminal region of T-ag can be identified by comparing maps of WT T-ag with maps of the T-ags encoded by
certain SV40 deletion mutants (7). SV40 d11263 contains a
deletion that falls within the carboxy-terminal, methioninecontaining tryptic peptide of WT T-ag (62). Thus, the spot
corresponding to this peptide should be absent on a map- of
the mutant T-ag. The map should also contain one extra spot
not found in WT T-ag, corresponding to the deleted version
of the WT peptide. A two-dimensional tryptic peptide map of
[35S]methionine-labeled T-ag from d11263-infected cells is
shown in Fig. 7A. Compared with the WT T-ag map (Fig.
7B), this map lacked one spot and contained one additional
spot, as expected. The missing spot was identified as the
carboxy-terminal, methionine-containing tryptic peptide of
WT T-ag (Fig. 7B, arrowhead). It was one of the 17 highly
reproducible peptides that are always found on maps of
T-ag. This peptide was clearly present on maps of mT-ag
(Fig. 5B), but was missing on the dlA2413 T*-ag map (Fig.
6B). This result strengthens and extends the interpretation
that T*-ag does not account for mT-ag. The data specifically
show that the carboxy termini of nT-ag and mT-ag are
structurally very similar, if not identical.

DISCUSSION
A challenging problem in the study of SV40 has been to
determine how T-ag, a single protein, mediates viral transformation of host cells. Although elucidation of the
multifunctional character of T-ag provided a basis for understanding this capability, it only served to redefine the problem. It is now necessary to determine at the molecular level
how T-ag performs a multitude of different functions. The
potential structural diversity of T-ag is a clue; distinct
subpopulations of T-ag exist and might be capable of mediating separate functions based upon their unique structural
features. Another clue is found in the recent suggestion that
T-ag species localized to different subcellular compartments
may provide distinct biological functions (23, 26, 27, 48). The
interpretation that both nT-ag and mT-ag are required for
transformation of primary cells, whereas mT-ag is sufficient
for transformation of established rodent cells (11, 27), represents an important link between the action of T-ag and the
products of other viral oncogenes. Previous studies have
suggested that certain of these proteins mediate distinct and
perhaps cooperative transformation-related functions that
appear to correlate with their localization within cells (21,
45).
Besides providing a possible basis for the functional
diversity of T-ag, the differential localization of T-ag also
poses an interesting transport problem. It would be useful to
know how T-ag molecules destined for the nucleus or plasma
membrane are recognized and directed to different
subcellular compartments.
In this study, we attempted to identify structural differences between nT-ag and mT-ag which might provide molecular signals for the recognition and differential transport
of these molecules. These proteins were mapped at a high
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FIG. 7. Two-dimensional analysis of the methionine-containing
tryptic peptides of WT T-ag and dl1263-encoded T-ag. T-ag was
isolated from whole-cell extracts of [35S]methionine-labeled cells
infected with WT SV40 or SV40 dl1263, and tryptic peptides were
prepared and analyzed as described in the legend to Fig. 5. (A)
d11263-specified T-ag. (B) WT T-ag. The arrowhead in panel B
indicates the carboxy-terminal, methionine-containing tryptic peptide in WT T-ag. A comparison with Fig. 5B reveals that the same
peptide was present in mT-ag.

level of sensitivity, and our results showed that nT-ag and
mT-ag are very similar or identical. No structural differences
that might serve as recognition signals were detected. We
must point out, however, that only methionine- and prolinecontaining peptides were examined. Although these peptides
account for approximately 60% of the T-ag molecule, a
structural difference could have been missed if it occurred in
a region of the protein lacking these amino acids. In addition,
in this study we did not specifically examine chemical
modifications for a potential structural difference between
nT-ag and mT-ag; such analyses are currently underway.
Thus, the mechanism of recognition and transport of T-ag
molecules destined for nuclei or plasma membranes remains
unclear. It is known that the primary amino acid sequence of
T-ag generates a strong nuclear transport signal, which is
located between amino acids 127 and 133 (16, 25). However,
it is unclear whether nT-ag and mT-ag both contain this
signal. The analyses described in this paper probably would
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not have revealed the absence of the nuclear transport signal
in mT-ag, unless a marked change had occurred around this
site. By using two-dimensional peptide mapping, we were
previously unable to demonstrate a structural difference
between the methionine-containing peptides of WT T-ag and
the methionine-containing peptides of a mutant T-ag defective for nuclear transport (15). It was subsequently shown
that the only difference between the two was a single amino
acid substitution at amino acid 128; a lysine in WT T-ag was
replaced by an asparagine in the mutant T-ag (25), and this
simple change had escaped detection on the peptide maps
because, among other reasons, the change fell within a
tryptic peptide lacking methionine. It would be useful to
know whether mT-ag expresses the nuclear transport signal,
as this signal might dictate the transient localization of
mT-ag in nuclei. This expectation is supported by the
demonstration that when the nuclear transport signal of T-ag
is fused to certain cytoplasmic proteins, it can mediate their
nuclear localization (17). Thus, mT-ag could conceivably be
derived from the nT-ag pool, a model that would require a
novel transport pathway between the nucleus and the plasma
membrane. Another possibility is that T-ag destined for the
membrane undergoes some subtle modification which negates the nuclear transport signal and reroutes the T-ag to
the plasma membrane. Such a modification might have
escaped detection in this study. Finally, there is the possibility that the small amounts of T-ag which associate with the
plasma membrane do so by simply escaping the strong
nuclear transport signal and entering another transport pathway. However, if membrane-associated T-ag provides a
critical function at this location, as current data suggest, it is
difficult to rationalize such a nonspecific mechanism of
transport. Studies are in progress to attempt to distinguish
between these possibilities and to ultimately define the
transport pathway utilized for the membrane localization of

T-ag.
It is clear from previous studies that at least one structural
difference does exist between nT-ag and mT-ag. A subpopulation of mT-ag is modified by fatty acid acylation whereas
nT-ag is not (19). This structural difference might explain the
minor differences in the peptide maps of iodinated nT-ag and
mT-ag previously reported by Schmidt-Ullrich et al. (50).
We did not observe this difference, suggesting that the
acylation site is located on a portion of T-ag that was not
surveyed by our methods (i.e., it is located within a V8 or
tryptic peptide lacking methionine and proline). Regardless,
we do not believe that acylation of mT-ag represents a signal
for differential transport of this molecule. Rather, the modification probably occurs after, and is a result of, the entry of
mT-ag into its transport pathway. Available evidence suggests that modification of proteins by palmitylation, the
acylation event characteristic of T-ag (19), occurs in the cis
portion of the Golgi apparatus (9, 49), and this organelle may
therefore be involved in the transport of mT-ag to the plasma
membrane. Alternatively, acylation may occur at the plasma
membrane itself by exchange between T-ag and membrane
lipids. This suggestion is supported by studies which have
shown that palmitylation occurs independently of protein
synthesis (30, 35) and can occur as long as 48 h after some
proteins are synthesized (39). In addition, exogenous T-ag
can apparently be palmitylated by association with the cell
surface (28).
A second purpose of the current study was to determine
whether the theoretical T*-ag represents mT-ag. Our results
strongly indicate that T*-ag does not account for the majority of mT-ag. The electrophoretic migration of a known
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T*-ag polypeptide was different from that of mT-ag. Furthermore, although we were able to identify T*-ag-specific
peptides, we failed to detect these peptides in digests of WT
mT-ag. This analysis was refined to the point where we were
able to specifically identify a tryptic peptide from the
carboxy-terminal portion of WT T-ag and could demonstrate
its presence in mT-ag and its absence in T*-ag. These results
confirmed and extended the results of a previous study in
which no evidence of T*-ag was detected among the tryptic
peptides of T-ag isolated from whole-cell extracts of SV40infected cells (7). The current study more specifically
showed that T*-ag does not account for mT-ag. In addition,
the two-dimensional tryptic peptide maps of WT T-ag and
dlA2413 T*-ag presented in this study are in agreement with
the maps recently prepared by Tevethia et al. (Virology, in
press). These authors detected three unique methioninecontaining peptides in maps of the T-ag encoded by dlA2414,
which, like dlA2413, encodes a protein similar to the hypothetical WT T*-ag.
Our data do not completely rule out the possibility that
T*-ag might be synthesized in very small amounts in infected
cells. However, it is unlikely that T*-ag plays an important
role in infection of cells by SV40. A recent study has shown
that dlA2413 T*-ag lacks the ability to bind the origin of
SV40 DNA and has no detectable ATPase activity, both of
which are probably required for the viral DNA replication
function of T-ag (Cole et al., submitted for publication). It is
also unlikely that T*-ag plays a critical role in transformation
of cells by SV40. Another recent study (M. J. Tevethia, J.
Pipas, and C. N. Cole, submitted) has shown that mouse
cells expressing dlA2414 T*-ag are not immortalized. Furthermore, dl2199, which cannot encode T*-ag due to the
absence of the requisite splice donor and acceptor sites in
the 3' region, immortalizes mouse cells with WT efficiency.
Thus, dlA2413 and dlA2414 T*-ags appear to be functionally
inert, even though they can enter the normal transport
pathways utilized for WT T-ag and become localized in both
the nucleus and plasma membrane (6a; Tevethia et al., in
press; Jarvis and Butel, unpublished data).
On the basis of this evidence, we suggest that a hydrophobic carboxy terminus is not necessary for the association of
T-ag with the plasma membrane. Studies in our laboratory
have shown that the membrane association of T-ag is dynamic; T-ag molecules associate unstably with the plasma
membrane, disappear, and are replaced with new T-ag
molecules (24, 47, 55). Other workers have reported that a
subpopulation of membrane-associated T-ag appears to be
more stable, probably as a result of its posttranslational
modification by fatty acid acylation (19). This event probably
anchors T-ag in the membrane through an interaction with
the lipid bilayer. Therefore, current knowledge is consistent
with a model that includes two populations of T-ag localized
at the plasma membrane. One population appears to be
transiently associated with the membrane, an association
probably mediated by the primary structure of the protein,
which does not have the capacity to mediate a stable
interaction. A second population, which may be a derivative
of the first, is more stably anchored in the membrane due to
fatty acid modification. This model of two closely related
mT-ag populations is consistent with the results of the
structural studies described here in that the existence of a
hydrophobic carboxy-terminal anchor sequence in mT-ag
was ruled out. Therefore, a stable interaction with the
membrane would require a modification, such as acylation,
and molecules lacking this modification might exhibit only a
transient association. Other support comes from the finding
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that a 28K truncated T-ag that is not acylated can associate
with the membrane, but is more easily extractable than other
forms of T-ag that do get acylated (20). It is possible that the
proposed subpopulations of mT-ag provide different biological functions, both of which might differ from the functions
provided by nT-ag. However, further investigation will be
required to examine this possibility.
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